Link to the original article Dr Upendra Kaul, Chairman Cardiology BHMRC co-chairs a path breaking study In the first randomized trial of an Indian-made stent versus the best-in-class Xience stent (Abbott) conducted in Europe, the Supraflex sirolimus-eluting stent (SMT; Surat, India) proved itself to be a worthy competitor in results presented here at TCT 2018. In the TALENT trial, the rate of a device-oriented composite endpoint of cardiac death, target-vessel MI, and clinically indicated TLR at 12 months was 4.9% with Supraflex and 5.3% with Xience, a difference that met criteria for noninferiority ( P < 0.001), study chair Patrick Serruys, MD, PhD (Imperial College London, England, and Erasmus University, Rotterdam, the Netherlands), reported. Though there were no significant differences between groups for any of the components of the composite outcome, a per-protocol analysis suggested that TLR might be lower with Supraflex, which is not available in the ...